oxazoles has been researched along with Diabetes Mellitus, Type 2 in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (7.59) | 18.2507 |
| 2000's | 34 (43.04) | 29.6817 |
| 2010's | 35 (44.30) | 24.3611 |
| 2020's | 4 (5.06) | 2.80 |
| Authors | Studies |
|---|---|
| Grobbee, DE; Heerspink, HJL; Koomen, JV; Lincoff, AM; Nicholls, SJ; Schrieks, IC; Schwartz, GG; Stevens, J; Svensson, A; Wedel, H; Weichert, A | 1 |
| Han, CL; Qu, CZ | 1 |
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
| Drosatos, K; Kalliora, C | 1 |
| Cosentino, F; Grobbee, DE; Lincoff, AM; Mellbin, L; Morici, N; Nozza, A; Perrone Filardi, P; Ponticelli, C; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC | 1 |
| Cavallini, C; Cosentino, F; Eijkemans, MJ; Ferri, M; Grobbee, DE; Lambers Heerspink, HJ; Lincoff, AM; Malmberg, K; Morici, N; Morocutti, G; Murena, E; Nozza, A; Perrone Filardi, P; Ryden, L; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC; Toyama, T | 1 |
| Dusaulcy, R; Gosmain, Y; Handgraaf, S; Philippe, J; Visentin, F | 1 |
| Buse, JB; Grobbee, DE; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Dong, T; Fukunaga, K; Ibata, T; Imachi, H; Iwama, H; Kobayashi, T; Lyu, J; Murao, K; Sato, S; Yonezaki, K; Yoshimoto, T; Zhang, G | 1 |
| Cha, DR; Cha, JJ; Han, JY; Hyun, YY; Kang, YS; Kim, HW; Kim, JE; Lee, JE; Lee, MH; Nam, DH; Song, HK | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Fukui, M; Hinoi, E; Ito, Y; Kitao, T; Kubo, M; Shirahase, H; Yoneda, Y | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A | 1 |
| Mearns, BM | 1 |
| Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D | 1 |
| Cersosimo, E; Coletta, DK; DeFronzo, RA; Fernandez, M; Gastaldelli, A; Musi, N | 1 |
| Andjelkovic, M; Buse, JB; Durrwell, L; El Azzouzi, B; Henry, RR; Herz, M; Jaekel, K; Mingrino, R; Wu, H | 1 |
| Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H | 1 |
| Andjelkovic, M; Fischer, A; Gastaldelli, A; Heise, T; Herz, M; Nosek, L; Stirban, AO | 1 |
| Cheng, XC; Liu, X; Wang, RL; Xie, XB; Zhang, J | 1 |
| Gao, F; Hu, M; Zheng, C | 1 |
| Fiedorek, FT; Ledeine, JM; Rubin, CJ | 1 |
| Achanzar, W; Cheng, P; Cosma, G; Delmonte, T; Dracopoli, NC; Geese, WJ; Hariharan, N; Hui, L; Krishnan, B; Ordway, N; Ranade, K; Rubin, C; Tomlinson, L | 1 |
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Charbonnel, B | 1 |
| Chognot, C; Henry, RR; Herz, M; Lincoff, AM; Mudaliar, S; Rabbia, M | 1 |
| Banken, L; Jamois, C; Liogier D'ardhuy, X; Sanwald-Ducray, P | 1 |
| De Pril, V; Fiedorek, FT; Rubin, CJ | 1 |
| Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K | 1 |
| Cavender, MA; Lincoff, AM | 1 |
| Gaspari, F; Herz, M; Perico, N; Rabbia, M; Urbanowska, T; Viberti, G; Wieczorek Kirk, D | 1 |
| Lecka-Czernik, B | 1 |
| Choe, SS; Choi, EB; Chung, H; Jeong, HW; Kim, HS; Kim, JB; Kim, KH; Kim, WS; Lee, GY; Lee, H; Lee, HK; Lee, JH; Lee, JW; Park, HS; Park, KS; Park, SB; Ro, S; Shin, D; Shin, HJ | 1 |
| Davis, SN; Uhl, L; Younk, LM | 1 |
| Casolaro, A; Cersosimo, E; DeFronzo, RA; Fernandez, M; Ferrannini, E; Gastaldelli, A; Hardies, J; Musi, N; Petz, R; Tantiwong, P; Triplitt, C | 1 |
| Akiyama, TE; Berger, JP; Castriota, G; Chang, CH; Chen, Y; Doebber, TW; Einstein, M; Lau, F; Li, Y; Liu, K; Liu, W; McCann, ME; McKeever, B; McNamara, L; Meinke, PT; Mosley, RT; Wang, C; Wood, HB; Wu, M; Zhou, G | 1 |
| Hao, M; Ji, M; Li, G; Li, Y; Luo, F; Ren, H; Yang, L; Zhang, S; Zhang, X | 1 |
| Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W | 1 |
| Wilding, JP | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Faillie, JL; Hillaire-Buys, D; Montastruc, JL; Petit, P | 1 |
| Chou, KC; Ma, Y; Wang, RL; Wang, SQ; Xu, WR | 1 |
| Heuman, AN; Scholl, JC; Wilkinson, K | 1 |
| Hao, M; Qiu, J; Zhang, S | 1 |
| Bogdański, P; Bryl, W; Cymerys, M; Kujawska-Łuczak, M; Miczke, A; Pupek-Musialik, D | 1 |
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Adrogue, JV; Brown, KK; Burgmaier, M; Golfman, LS; Guthrie, PH; Sharma, S; Taegtmeyer, H; Van Arsdall, M; Wilson, CR; Young, ME | 1 |
| Buse, JB; Davidson, JA; Frederich, R; Lin, KC; Montoro, R; Rubin, CJ; Shockey, G; Viraswami-Appanna, K | 1 |
| Nissen, SE; Topol, EJ; Wolski, K | 1 |
| Brophy, JM | 1 |
| Kordella, T | 1 |
| Cox, SL | 1 |
| Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
| Cao, YL; Li, S; Liu, HY; Wang, LL; Xu, C; Zhou, XB | 1 |
| Lebovitz, H | 1 |
| Heinzl, S | 1 |
| Liebson, PR | 1 |
| Belder, R; DeFronzo, RA; Fiedorek, FT; Gross, J; Kendall, DM; Ledeine, JM; Mohideen, P; Norwood, P; O'Mahony, M; Roberts, A; Rubin, CJ; Sall, K; Sloan, G | 1 |
| Beckey, C; Parra, D; Thomas, T | 1 |
| Najman, DM | 1 |
| Doggrell, SA | 1 |
| Fiévet, C; Fruchart, JC; Staels, B | 1 |
| Hong, G; Hughes, A; Lin, X; McCarthy, A; McCarthy, L; Mosteller, M; Sathe, G; Smart, D; Spraggs, C; Traini, C; Van Horn, S; Warren, L | 1 |
| Aoki, T; Asaki, T; Hamamoto, T; Kuwabara, K; Murakami, K; Ohmachi, S; Sugiyama, Y; Todo, M | 1 |
| Clark, DA; Genereux, PE; Gibbs, EM; Hulin, B; Lewis, DM; Newton, LS | 1 |
| Ishikawa, Y; Takagi, Y; Takeno, H; Tani, T; Watanabe, K | 1 |
| Ikemoto, T; Ishikawa, Y; Saito, MN; Takeno, H; Tani, T; Watanabe, K | 1 |
| Aicher, TD; Balkan, B; Bell, PA; Brand, LJ; Cheon, SH; Deems, RO; Fell, JB; Fillers, WS; Fraser, JD; Gao, J; Kahle, GG; Knorr, DC; Leone, CL; Nadelson, J; Simpson, R; Smith, HC | 1 |
| Ishikawa, Y; Takeno, H; Tani, T; Watanabe, K | 1 |
| Bauduceau, B; Dupuy, O; Mayaudon, H | 2 |
| Flam, BR; Gunawan, I; Malamas, MS; Mihan, B; Sawicki, DR; Seestaller, L; Sredy, J; Sullivan, D | 1 |
| Desai, RC | 1 |
13 review(s) available for oxazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Lipids; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Thiophenes; Treatment Outcome; Weight Gain | 2020 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
Multitargeted bioactive ligands for PPARs discovered in the last decade.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Isoquinolines; Ligands; Oxazoles; PPAR alpha; PPAR delta; PPAR gamma | 2016 |
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
Topics: Aged; Animals; Antitubercular Agents; Arrhythmias, Cardiac; Comorbidity; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diarylquinolines; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Middle Aged; Nitroimidazoles; Oxazoles; Polypharmacy; Risk Assessment; Risk Factors; Tuberculosis | 2016 |
Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes | 2010 |
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
Topics: Apolipoproteins B; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Fibric Acids; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Triglycerides | 2011 |
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
Topics: Adult; Aged; Animals; Area Under Curve; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Glycine; Half-Life; Humans; Hypoglycemic Agents; Male; Oxazoles; Peroxisome Proliferator-Activated Receptors; Tissue Distribution | 2005 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Muraglitazar and the FDA: what constitutes drug safety?
Topics: Animals; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Oxazoles; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2006 |
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Topics: Alkanesulfonates; Animals; Diabetes Mellitus, Type 2; Glycine; Humans; Metabolic Syndrome; Models, Biological; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
26 trial(s) available for oxazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Risk Factors; Thiophenes | 2020 |
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Analysis of Variance; Biomarkers; Cause of Death; Comorbidity; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Oxazoles; Patient Discharge; Percutaneous Coronary Intervention; Peroxisome Proliferator-Activated Receptors; Predictive Value of Tests; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Thiophenes | 2017 |
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Revascularization; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome | 2018 |
Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Thiophenes | 2018 |
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome | 2018 |
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2013 |
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2014 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Renal Insufficiency, Chronic; Therapeutic Equivalency; Thiazolidinediones; Thiophenes | 2014 |
The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
Topics: Adiponectin; AMP-Activated Protein Kinases; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycine; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Oxazoles; Oxidation-Reduction; PPAR alpha; PPAR gamma; Signal Transduction; Triglycerides | 2015 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Thiophenes | 2015 |
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome | 2015 |
Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipid Metabolism; Metabolic Syndrome; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes; Treatment Outcome | 2016 |
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2008 |
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Diabetes Mellitus, Type 2; Edema; Endothelin-1; Female; Gene Expression Regulation; Glycine; Humans; Macaca fascicularis; Male; Oxazoles; Pharmacogenetics; Polymorphism, Single Nucleotide; PPAR gamma; Regression Analysis; Renin | 2008 |
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Topics: Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Safety; Single-Blind Method; Thiazolidinediones; Thiophenes; Treatment Outcome | 2009 |
Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
Topics: Aged; Area Under Curve; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxazoles; Socioeconomic Factors; Thiophenes | 2010 |
Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Time Factors; Treatment Outcome | 2009 |
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Time Factors; Treatment Outcome; Weight Gain | 2009 |
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Oxazoles; Prognosis; Renal Insufficiency; Retrospective Studies; Thiophenes; Young Adult | 2011 |
Metabolic effects of muraglitazar in type 2 diabetic subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Intra-Abdominal Fat; Male; Middle Aged; Oxazoles; Peroxisome Proliferator-Activated Receptors | 2011 |
[The effect of analysed hypotensive drugs on certain metabolic parameters].
Topics: Adult; Antihypertensive Agents; Diabetes Mellitus, Type 2; Felodipine; Female; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Indoles; Male; Metabolic Syndrome; Middle Aged; Oxazoles; Rilmenidine | 2003 |
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Oxazoles; Peroxisome Proliferator-Activated Receptors | 2005 |
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A
Topics: Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar.
Topics: Adult; Aged; Base Sequence; Diabetes Mellitus, Type 2; DNA Primers; Edema; Epithelial Sodium Channels; Female; Genes, Reporter; Genetic Variation; Humans; Male; Middle Aged; Oxazoles; Pharmacogenetics; Phenotype; PPAR gamma; Promoter Regions, Genetic; Risk Factors; Time Factors; Tyrosine | 2007 |
Efficacy of rilmenidine versus captopril on microalbuminuria: a pilot study in hypertensive type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Captopril; Diabetes Mellitus, Type 2; Humans; Hypertension; Oxazoles; Pilot Projects; Random Allocation; Rilmenidine | 1999 |
Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure Determination; Captopril; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Oxazoles; Pilot Projects; Rilmenidine | 2000 |
40 other study(ies) available for oxazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |
17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Estradiol; Estrogen Receptor beta; Female; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucose Tolerance Test; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ovariectomy; Oxazoles; Phenols; Primary Cell Culture | 2018 |
Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells.
Topics: Animals; ATP Binding Cassette Transporter 1; Benzoxazoles; Butyrates; Cell Line, Tumor; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Glucose; Glucose Intolerance; Humans; Hypolipidemic Agents; Insulin; Insulin-Secreting Cells; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Oxazoles; PPAR alpha; Promoter Regions, Genetic; Rats; RNA, Messenger; Tyrosine | 2018 |
Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice.
Topics: 3T3-L1 Cells; Acetates; Adipocytes; Albuminuria; Animals; Blotting, Western; Cells, Cultured; Cytokines; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression; Glucose; Inflammation Mediators; Insulin Resistance; Kidney; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Oxazoles; Podocytes; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Toll-Like Receptor 4 | 2013 |
Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
Topics: Adipocytes; Animals; Bone Density; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Isoquinolines; Osteoblasts; Osteoporosis, Postmenopausal; Ovariectomy; Oxazoles; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Inbred F344; Receptor, Insulin; Risk; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Acute coronary syndromes: Aleglitazar trial findings reported.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Oxazoles; Thiophenes | 2014 |
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Thiophenes | 2009 |
Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk Factors; Thiophenes | 2010 |
A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
Topics: Analysis of Variance; Animals; Body Weight; Carbohydrate Metabolism; Cell Line; Computer Simulation; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Lipid Metabolism; Liver; Mice; Myocardial Reperfusion Injury; Oxazoles; PPAR alpha; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidines; Transfection | 2011 |
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Topics: Animals; Benzimidazoles; Binding Sites; Chlorocebus aethiops; COS Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dimethadione; Drug Partial Agonism; Gene Expression Profiling; Humans; Hypoglycemic Agents; Male; Mice; Models, Molecular; Mutagenesis; Nuclear Receptor Coactivators; Oxazoles; Pioglitazone; PPAR gamma; Protein Conformation; Rats; Rats, Zucker; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation | 2011 |
In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fructose-Bisphosphatase; Hydrogen Bonding; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxazoles; Quantitative Structure-Activity Relationship; Sequence Alignment; Thiazoles | 2011 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2012 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Thiazolidinediones; Urinary Bladder Neoplasms | 2012 |
Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Topics: Binding Sites; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Ligands; Models, Molecular; Molecular Conformation; Molecular Dynamics Simulation; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Protein Structure, Tertiary; Tyrosine | 2012 |
Rural Hispanic populations at risk in developing diabetes: sociocultural and familial challenges in promoting a healthy diet.
Topics: Adolescent; Adult; Child; Culture; Diabetes Mellitus, Type 2; Diet; Family; Feeding Behavior; Female; Focus Groups; Health Promotion; Hispanic or Latino; Humans; Male; Obesity; Oxazoles; Psychology; Pyridines; Risk Factors; Rural Population | 2013 |
Toward the prediction of FBPase inhibitory activity using chemoinformatic methods.
Topics: Algorithms; Computational Biology; Computer Simulation; Diabetes Mellitus, Type 2; Drug Discovery; Fructose-Bisphosphatase; Humans; Inhibitory Concentration 50; Models, Molecular; Models, Statistical; Oxazoles; Quantitative Structure-Activity Relationship; Regression Analysis | 2012 |
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.
Topics: Adaptation, Physiological; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Metabolism; Gene Expression Regulation; Glucose; In Vitro Techniques; Insulin Resistance; Male; Myocardial Contraction; Myocardium; Oxazoles; PPAR gamma; Rats; Rats, Inbred Strains; Rats, Zucker; Signal Transduction; Transcriptional Activation; Triglycerides; Tyrosine | 2005 |
Molecule of the month. Muraglitazar.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Oxazoles; PPAR alpha; PPAR gamma | 2005 |
Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Metabolic Syndrome; Oxazoles; Pioglitazone; Thiazolidinediones; United States | 2005 |
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Selling safety--lessons from muraglitazar.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; United States; United States Food and Drug Administration | 2005 |
One pill, two conditions.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypercholesterolemia; Oxazoles; United States | 2005 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Blood Glucose; Cell Differentiation; Cell Line; Cholesterol; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Furans; Glucose Transporter Type 4; Hepatocytes; Humans; Insulin Resistance; Lipid Metabolism; Lipoprotein Lipase; Male; Mice; Oxazoles; PPAR alpha; PPAR gamma; RNA, Messenger; Triglycerides | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Oxazoles; PPAR alpha; PPAR gamma | 2006 |
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Middle Aged; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Weight Gain | 2006 |
A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments.
Topics: Animals; Atherosclerosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Ethics, Clinical; Glycine; Heart Failure; Humans; Indoleacetic Acids; Myocardial Infarction; Oxazoles; Prostheses and Implants; Stroke; Treatment Failure; Ultrasonography | 2006 |
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred Strains; Molecular Structure; Oxazoles; PPAR alpha; Structure-Activity Relationship; Triglycerides | 2008 |
Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone.
Topics: 3T3 Cells; Adipocytes; Animals; Benzofurans; Carboxylic Acids; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Mice; Mice, Mutant Strains; Mice, Obese; Molecular Structure; Oxazoles; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1996 |
Actions of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic db/db mice.
Topics: 3T3 Cells; Adipocytes; Administration, Oral; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drinking; Eating; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Obese; Monosaccharide Transport Proteins; Oxazoles; Phenylalanine | 1998 |
Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals.
Topics: Administration, Oral; Animals; Deoxyglucose; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred Strains; Oxazoles; Phenylalanine; Rats; Rats, Inbred Strains; Rats, Wistar | 1998 |
Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Muscles; Oxazoles; Pyrroles; Rats; Structure-Activity Relationship; Thiazoles | 1998 |
Lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice.
Topics: Adipose Tissue; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Epididymis; Fatty Acids, Nonesterified; Glucose; Hypoglycemic Agents; Insulin; Lipids; Male; Mice; Mice, Inbred ICR; Mice, Obese; Oxazoles; Phenylalanine | 1999 |
New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties.
Topics: 4-Nitrophenylphosphatase; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Liver; Male; Membrane Proteins; Mice; Mice, Obese; Oxazoles; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Structure-Activity Relationship | 2000 |
Non-thiazolidinedione insulin sensitiser shows promise.
Topics: Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Multicenter Studies as Topic; Oxazoles; Thiazoles; Tyrosine | 2000 |
A convenient synthesis of the novel hypoglycemic agent SDZ PGU 693.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; Pyrroles | 2001 |